Back

Cardiovascular prevention with GLP1 agonists in high or very-high cardiovascular risk irrespective of diabetes.

31 August 2024 (09:27 - 09:45)
Organised by: Logo
Congress Presentation Part of: Obesity and pre-diabetes: where do we stand today on prevention and treatment? Secondary Prevention ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Nicolas del-Cuerpo-Salinas

UNIVERSITY HOSPITAL SAN JUAN DE ALICANTE, Sant Joan d'Alacant (Spain)

4 More presentations in this session

Presentation thumbnail
State-of-the-art lecture on obesity and pre-diabetes: where do we stand today on prevention and treatment?
Professor E. Prescott (Copenhagen, DK)
Slides Video
Presentation thumbnail
Are metabolically healthy obese individuals really a benign cardiovascular group? An analysis of 162,590 participants with measures of arterial stiffness in UK BIOBANK
Doctor R. Ananda (Melbourne, AU)
Abstract Slides Video
Presentation thumbnail
Association between normal range UACR and insulin resistance and prediabetes among US adults:
Miss S. Wu (Beijing, CN)
Abstract Slides Video
Presentation thumbnail
Exploratory mediation analysis of the effect of semaglutide on cardiovascular outcomes in people with overweight or obesity in the SELECT randomised trial
Professor S. Kahn (Seattle, US)
Abstract Slides Video

Access the full session

Session thumbnail
Obesity and pre-diabetes: where do we stand today on prevention and treatment?
Video

The Event

Event poster

ESC Congress 2024

31 August 2024 09:27 CET
You may be interested in
thumbnail
Congress Session
What's new for GLP-1 agonist and SGLT2 inhibitor cardiovascular pharmacotherapy?
thumbnail
Congress Presentation
Heart failure and renal outcomes in patient treated with GLP1 agonists.
thumbnail
Congress Session
Late-Breaking Clinical Science: cardiometabolic medicine

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources